Homocysteine (Hcy) is an intermediary metabolite that arises from the metabolism of the essential dietary protein amino acid methionine (Met). Hcy levels are regulated by remethylation to Met, catalyzed by Met synthase (with methyltetrahydrofolate cofactor provided by the MTHFR enzyme) and betaine-Hcy methyltransferase, as well as by transsulfuration to cysteine, the first step of which is catalyzed by cystathionine β-synthase (CBS) (1) .
Hcy is also metabolized to the thioester Hcy-thiolactone in an error-editing reaction in protein biosynthesis when Hcy is erroneously selected in place of Met by methionyl-tRNA synthetase (MetRS) (2). Hcy-thiolactone forms isopeptide bonds with protein lysine residues, generating N-Hcyprotein in a process called N-homocysteinylation (3) (4) (5) .
Genetic or nutritional deficiencies in Hcy metabolism lead to hyperhomocysteinemia (HHcy) characterized by the accumulation in the blood and tissues of Hcy, Hcy-thiolactone and N-Hcyprotein, which have been linked to neurological and cardiovascular diseases (6) . For example, Hcythiolactone is a predictor of acute myocardial infarction in patients with angiographically confirmed cardiovascular disease in a large randomized controlled clinical trial with over 2000 patients (7) .
In humans, severe HHcy due to CBS deficiency causes connective tissue abnormalities in most body systems, including bones and vasculature (1) . HHcy due to MTHFR deficiency has also been linked to bone abnormalities in humans (8, 9) . Similar connective tissue abnormalities affecting bones are also observed in Cbs -/-mice (10, 11).
Collagen is a major component of fibrous connective tissues such as tendons and bone (12) .
It is the most abundant protein and accounts for 25-35% of total body protein content in mammals.
Collagenous fibers provide structural support and resistance to stretch forces. Mechanical properties of collagenous fibers come from specific inter-chain crosslinks involving lysine residues within and between collagen chains (13) . The crosslink formation is initiated by the conversion of specific lysine and hydroxylysine resides to the aldehydes allysine and hydroxyallysine, respectively, catalyzed by lysine oxidase (LOX) (14, 15) . The allysine or hydroxyallysine and ε-amino group of a neighboring lysine residue react spontaneously to form a Schiff-base adduct, which matures into a stable pyridinoline crosslink (16) . There are one to two crosslinks per triple helical collagen unit. The main fibril-forming collagens (type I, II, and III) have four cross-linking sites, one in each of the short nonhelical ends of collagen molecules (telopeptides) and two in the triple helical region, close to its Nand C-terminal ends. The pyridinoline crosslinks occur in bone, skeletal tissues, and cartilage collagens and provide the tensile strength and mechanical stability of collagen fibrils, required for normal function of connective tissues (12, 13) .
Mechanisms by which HHcy causes connective tissue abnormalities are not understood.
Because collagen lysine residues are involved in crosslink formation, N-homocysteinylation of these lysines should impair crosslinking (3, 17) . To examine this prediction, we studied collagen Nhomocysteinylation and crosslinking in tissues of Cbs -/-mice and their Cbs +/-littermates.
MATERIALS AND METHODS

Mice
Transgenic Tg-I278T Cbs -/-mice on C57BL/6J genetic background (11) and their Cbs +/-littermates were bred and housed at the Rutgers-New Jersey Medical School Animal Facility. In these animals, the human CBS-I278T variant is under control of the zinc-inducible metallothionein promoter, which allows rescue the neonatal lethality phenotype of Cbs -/-in mice by supplementing the drinking water of pregnant dams with 25 mM zinc chloride. Zinc water is replaced by plain water after weaning.
Tg-I278T Cbs
-/-mice exhibit facial alopecia, osteoporosis (rough periosteal surface and small holes in femur, reduced trabecular bone mass, decreased bone mineral density), endoplasmic reticulum stress in the liver and kidney, and life span reduced by 20% (11) . tHcy, S-Hcy, and N-Hcy assays tHcy, S-Hcy, and N-Hcy were assayed by the conversion to Hcy-thiolactone, which was then separated by cation exchange HPLC, post-column derivatized with OPA, detected and quantified by fluorescence as previously described (18). Agilent Infinity 1260 system, containing HiP degasser, binary pump, high performance auto-sampler, thermostated column compartment, diode array detector, and fluorescence detector was used. Samples (5 µL) were injected into Poly CAT A column, 35x2.1 mm, 5 µM, 300 Å (Poly LC).
Plasma and urinary tHcy assays
Mouse plasma or urine (10 µL) was diluted to 100 µL with 20 mM K 2 HPO 4 , 2 mM dithiothreitol (DTT), and ultra-filtered on Amicon 10 kD cut off devices (4°C, 14,000 g, 30 min Urinary Hcy-thiolactone and N-Hcy-protein assays Urine (10 µL) was neutralized with K 2 HPO 4 . Hcy-thiolactone was extracted from the neutralized urine using the chloroform/methanol method (19, 20) and quantified by HPLC (21) . To quantify N-Hcyprotein, the neutralized urine (10 µL) was diluted 50-fold, treated with 2 mM DTT, and free Hcy removed by ultrafiltration using 3 kDa molecular weight cut-off Sartorius centrifugal ultrafiltration devices. The dilution-ultrafiltration cycle was repeated 5 more times to assure complete removal of free Hcy, confirmed by quantifying Hcy in protein-free filtrates. N-Hcy-protein was hydrolyzed under reducing conditions, under which liberated N-linked Hcy is quantitatively converted to Hcythiolactone, which was then extracted with chloroform/methanol, and quantified by cation exchange HPLC (22) .
Tissue tHcy and N-Hcy-protein assays
Frozen mouse tissue (about 50 mg) was transferred to 10 volumes of ice-cold 20 mM potassium phosphate buffer (pH 7.4), 0.2 mM EDTA containing protease inhibitor mixture (Sigma-Aldrich) and disintegrated by sonication on wet ice. Bone (hind leg tibia and femur) was pulverized with dry ice using a pestle and mortar pre-chilled to -80°C, prior to sonication. Crude extracts were clarified by centrifugation (15,000g, 15 min) and supernatants and pellets were saved. Protein in the supernatant was quantified using a Coomassie protein assay reagent (Sigma-Aldrich) according to the Bradford method (23).
To quantify tissue tHcy, the supernatant (50 µL) was treated with 25 mM DTT, 20 mM K 2 HPO 4 (50 µL) and deproteinized by ultrafiltration using Amicon 10 kDa molecular weight cut-off devices.
Reduced Hcy in the protein-free filtrate (30 µL) was converted to Hcy-thiolactone by the treatment with DTT (2 µL 0.25 M) and HCl (5 µL 6N, 100°C, 30 min). In parallel, D,L-Hcy standards (1.25-10 µM in 20 mM K 2 HPO 4 ) were treated in the same manner. After the conversion, reaction mixtures were dried under vacuum using a Labconco Centri-Vap concentrator, dissolved in deionized water, and
Hcy-thiolactone was quantified by HPLC.
To quantify tissue N-Hcy-protein, free Hcy was removed from the protein left on ultrafiltration devices by 4 cycles of dilution with 450 µL 20 mM K 2 HPO 4 , 2 mM DTT and ultrafiltration. After the last cycle, protein was quantified using the Bradford method, transferred to a glass ampule, and hydrolyzed with 6 N HCl, 20 mM DTT (120°C, 1 h). The hydrolysats were dried and stored at -80°C for Hcy-thiolactone quantification. To quantify N-Hcy, collagen pellets were washed twice with 20 mM K 2 HPO 4, 2 mM DTT (500 µL) to remove residual free Hcy, dried, and hydrolyzed with 6 N HCl, 30 mM DTT (120°C, 1 h). The hydrolysates were dried, the resulting Hcy-thiolactone was solid-phase extracted (see below), and quantified by cation exchange HPLC (22) .
S-and N-Hcy determination in bone collagen
Solid phase extraction of Hcy-thiolactone from protein hydrolysates
Hcy-thiolactone was extracted from tissue protein hydrolysates using reversed phase C18 sorbent in Empore C18-SD, 7 mm/3 mL extraction disk cartridge (Supelco). The C18 sorbent was first conditioned with acetonitrile, water and 10 mM sodium phosphate, pH 7.7 (500 µL each). Dried protein hydrolysates were dissolved in 50 µL of 1M K 2 HPO 4 , diluted to 1 mL with 10 mM sodium phosphate, pH 7.7, and transferred into the extraction disk cartridge. Because under these conditions Hcy-thiolactone is neutral (pK a =6.67, (25) ), it is retained on a C18 sorbent. After unbound substances were washed off the cartridge with 500 µL of 10 mM sodium phosphate, pH 7.7, Hcy-thiolactone was eluted with 500 µL of 70% acetonitrile containing 0.02 M HCl. At acidic pH Hcy-thiolactone becomes positively charged and is released from the C18 sorbent (20) . Eluents were dried and stored at -80°C
for Hcy-thiolactone quantification by cation exchange HPLC (22) .
Determination of pyridinoline crosslinks
Collagen pyridinoline crosslinks were quantified by HPLC (26) . Collagen was acid-hydrolyzed (6 N HCl, 110°C, 24 h) and pyridinolines were separated on a cation exchange polysulfoethyl aspartamide (PSEA) column, 100x2.1 mm, 3 µM, 300 Å (Poly LC) using a salt gradient at flow rate 0.36 mL/min at 24°C. Solvent A was 0.1% trifluoroacetic acid, solvent B, 1 M NaCl. The gradient was as follows: 15%
to 50% B for 8 min, 50% B from 8 to 9 min, and re-equilibration with 15 % B from 9.1 to 11 min.
Pyridinoloine (Pyd) and deoxypyridinoline (Dpd) elute as a single peak, detected and quantified by fluorescence with excitation at 295 nm and emission at 395 nm. Authentic Pyd and Dpd (cat. no.
8004, Quidel Corp., San Diego, CA) were used as standards.
Hydroxyproline assay
Hydroxyproline (Hyp) was quantified using the chloramine method (27) . Protein hydrolysates ( 
Cross-linked C-telopeptide of type I collagen and carboxyterminal propeptide of type I procollagen assays
Cross-linked C-telopeptide of type I collagen (CTXI) and procollagen I C-terminal propeptide (PICP) in mouse plasma were quantified using commercial Enzyme-linked Immunosorbent Assays kits (CloudClone Corp. and Blue Gene, respectively), in which tested CTXI or PICP from samples competes with horse radish peroxidase-labeled CTXI or PICP for binding to a CTXI-or PICP-specific antibody precoated onto a microplate. Samples were analyzed in duplicates following manufacturer's protocol.
Analysis of collagen N-homocysteinylation by mass spectrometry
Rat tail or mouse bone collagen type I (10 mg/ml) was modified with L-Hcy-thiolactone (10 mM) (Sigma-Aldrich) in 0.1 M phosphate buffer pH 7.4 as previously described (28) . Resulting N-Hcy- Mouse bone collagen was isolated from Cbs -/-and wild type animal using the acetic acid/pepsin extraction method (29) and processed as above to generate tryptic peptides (30) . Tryptic peptides were concentrated and desalted on a RP-C18 pre-column (Waters).
Analyses of collagen tryptic peptides were carried by LC-MS/MS. Peptides were separated on a nano-Ultra Performance Liquid Chromatography (UPLC) RP-C18 column (Waters, BEH130 C18 column, 25 cm x 75 µm i.d.) using a nanoACQUITY UPLC system, and a 160-min gradient of 5-30 % acetonitrile at a 300 nl/min flow rate.
The UPLC system was interfaced with micrOTOF-q mass spectrometer electrospray ionization was estimated using a joined target/decoy database search approach, false discovery rate was set below 1%.
LOX activity assay
We used LOX activity assay kit (Abcam, ab112139) to quantify LOX activity in the heart and liver of Cbs -/-and Cbs +/-mice. The assay quantifies hydrogen peroxide generated by LOX using a proprietary red fluorescence substrate in a horseradish peroxidase-coupled reaction.
Mouse tissues (heart, 30 mg; liver, 50 mg) were homogenized by sonication with 10 volumes of ice-cold RIPA buffer containing protease inhibitors (Sigma-Aldrich LOX activity is expressed as fluorescence units/min/µg protein.
Real-time PCR
Total RNA was extracted using Total RNA Purification Kit (Novazym), treated with DNase I (Thermo Scientific), and retrotranscribed using RiverAid Reverse Transcriptase (Thermo Scientific).
Quantitative real-time PCR reactions were carried out using Eppendorf Each reaction was carried out in duplicate for at least three individual mice of each Cbs genotype.
The Pfaffl method (32) was used to calculate the relative Lox mRNA level normalized to Gapdh or β-actin mRNA level.
Statistics
Data are expressed as means±SD. For non-normally distributed variables, data were log-transformed.
Comparisons between genotype groups were analyzed using a two-sided Student's t-test.
RESULTS
Cbs deficiency elevates plasma and urinary Hcy-thiolactone and N-Hcy-protein in mice
CBS-deficient patients are known to exhibit homocystinuria and HHcy. Similar to CBS-deficient humans, homozygous Cbs-deficient mice exhibit the HHcy phenotype (11, 33) (17, 35) .
Plasma N-Hcy-protein was elevated 11-fold, as previously described (34) . Urinary N-Hcy-protein was 30-fold higher in Cbs -/-mice than in Cbs +/-animals.
S-and N-homocysteinylation status of mouse collagen
We asked whether collagen is targeted for N-homocysteinylation and whether such collagen modification might be affected by inactivation of the Cbs gene. To answer these questions we set out to detect and quantify N-Hcy in collagen from Cbs -/-mice and their Cbs +/-littermates.
We found that N-Hcy was present in total bone collagen preparations from Cbs +/-mice at 3.3
pmol N-Hcy/μg bone collagen. In Cbs -/-mouse, N-Hcy increased 14.6-fold to 49 pmol N-Hcy/μg bone collagen (Fig. 1A) . We also found that acid-soluble tail collagen from Cbs +/-mice contained 0.7 pmol N-Hcy/μg collagen, which increased to 58 pmol N-Hcy/μg collagen in Cbs -/-animals (Fig. 1B) .
Because Hcy is known to also bind to protein cysteine residues via disulfide bonds, we addressed a question of whether a disulfide-bound Hcy occurs in collagen. However, because mature collagen type I does not contain cysteine residues, we predicted that the only thiol groups that might be present in collagen molecules and engage in disulfide bond formation with free Hcy would come from the N-Hcy residues. To test this prediction we quantified S-Hcy in bone and tail collagen.
We found that S-Hcy levels in bone, tail, and heart collagen were equal to, or lower than, the In total heart collagen of Cbs +/-mice, S-Hcy was lower than N-Hcy (0.18 vs. 1.5 pmol N-Hcy/μg heart collagen, P=0.002; Fig 1C) .
In Cbs -/-mice, both S-and N-Hcy were elevated; however, the S-and N-Hcy values were not significantly different from each other in the total bone collagen (30 vs. 49 pmol N-Hcy/μg bone collagen, P=0.31; Fig 1A) and acetic acid-soluble tail collagen (15.7 vs. 59 pmol N-Hcy/μg tail collagen, Fig 1B) , while in total heart collagen, S-Hcy tended to be lower than N-Hcy (4.4 vs. 20.5 pmol N-Hcy/μg heart collagen, P=0.07; Fig 1C) .
P=0.31;
Identification of collagen lysine residues susceptible to N-homocysteinylation in vitro and in vivo
To demonstrate that collagen is susceptible to N-homocysteinylation, we modified rat tail collagen type I with 50-fold molar excess of Hcy-thiolactone in vitro. Modified collagen was reduced, derivatized, digested with trypsin, and subjected to LC-MS/MS analyses. Using the IAA-derivatization procedure, we identified seven N-Hcy-peptides (Table II) , five in collagen type I alpha 1 chain (Col1A1) two in alpha 2 chain (Col1A2). Sequence coverage was 12% and 13% for Col1A1 and Col1A2, respectively. The N-Hcy-Lys residues were located at positions K160, K266, K583, K1085, K1225 in Col1A1 and positions K1070, K1146 in Col1A2. Residues K160 and K266 were also found to be Nhomocysteinylated using the MMTS procedure (Table II) . Two N-Hcy-Lys residues are located in the N-terminal (K 266 ) and C-terminal (K 1085 ) helical regions, one in the middle (K 583 ), and one (K 160 ) is located in the non-helical telopeptide region (Fig. 2) (36) .
We also analyzed by LC-MS/MS tryptic peptides from collagen type I isolated from bones of Cbs -/-mice using the MMTS procedure. We identified one N-Hcy-peptide in Col1A1 containing N-HcyLys residue at position K160 (Table III) . Sequence coverage was 14-24%. Treatment of mouse bone collagen with Hcy-thiolactone led to N-homocystienylation of two additional residues: K266 in and K1070 in Col1A2 (Table III, Fig. 2 ). These results suggest that K160 is a predominant site of collagen
N-homocysteinylation in vivo.
Interestingly, the K160 residue in mouse Col1A1 corresponds to K170 in human Col1A1 that is known to be involved in pyridinoline crosslink formation (13) .
Cbs gene inactivation affects collagen levels
In assessing effects of the Cbs gene inactivation on collagen crosslinking it is important to consider a possibility of changes in collagen levels in Cbs -/-mice relative to Cbs +/-animals. Thus, we quantified collagen levels in mouse tissues by hydroxyproline (Hyp) measurements in hydrolysates of collagen preparations from Cbs -/-mice and their Cbs +/-littermates. We found that collagen levels were significantly elevated in the heart (0.33 vs. 0.15 μg Hyp/mg heart, P=0.0003) (Fig. 3A) and tail (13.6 vs. 9.3 μg Hyp/mg dry tail, P=0.0003) (Fig. 3B) of Cbs -/-mice relative to Cbs +/-animals. In bone, collagen levels tended to be elevated in Cbs -/-relative to Cbs +/-mice (0.90 vs. 0.65 μg Hyp/mg bone, P=0.14) (Fig. 3A) .
Cbs gene inactivation reduces collagen crosslinking
In order to examine whether HHcy affects collagen crosslinking we used a UPLC-based assay to (Fig. 4) .
Collagen turnover
Connective tissue defects observed in HHcy could also be due to deranged collagen turnover. Tissue collagen turnover generates free and peptide-bound Dpd, which are released into the blood. To determine effects of HHcy due to Cbs deficiency on collagen degradation we quantified total Dpd using a competitive enzyme-linked immunoassay. Prior to the assay samples were acid-hydrolyzed to liberate Dpd from collagen peptides. We found that plasma Dpd levels were significantly reduced in Cbs -/-mice relative to their Cbs +/-littermates (0.92 vs. 2.74 nM, P=0.0003) (Fig. 5) .
To further examine how Cbs deficiency affects collagen synthesis and degradation, we quantified plasma procollagen I C-terminal propeptide (PICP) and carboxyterminal telopeptide of collagen type I (CTX I) in Cbs -/-mice and their wild type littermates using a competitive enzyme-linked immunoassays. PICP, a marker of collagen synthesis, is cleaved off from procollagen during collagen biogenesis. CTX I, a marker of collagen turnover, contains sites of Dpd crosslinking and is cleaved off during type I collagen degradation in tissues; its serum levels are highly correlated to collagen turnover rate. As shown in We also quantified Lox mRNA by RT-qPCR. We found that Lox mRNA expression in the heart of Cbs -/-mice was elevated 1.88±0.18-fold relative to and Cbs +/-animals using Gapdh mRNA as a reference (Fig. 6) . To confirm this finding, we additionally quantified Lox mRNA using β-actin as a reference and found that the results were similar: Lox mRNA was elevated 2.36±0.16-fold in Cbs -/-mice relative to Cbs +/-animals ( Fig. 6) . Taken together, these findings strongly suggest that neither Lox expression nor activity contribute to reduced levels of collagen crosslinks in Cbs -/-mice.
DISCUSSION
Since the discovery of clinical cases of severe HHcy in the 1960s, CBS deficiency has been known to cause connective tissue abnormalities (1). However, the underlying mechanism of these abnormalities was unknown. Since lysine residues are involved in intermolecular collagen crosslinking, we predicted that modification of collagen lysines by Hcy-thiolactone would impair crosslinking.
We used a Cbs -/-mouse model that recapitulates connective tissue abnormalities observed in CBS-deficient patients (11) . We found that: 1) mouse bone, tail, and heart collagen is N- Collagen fibril assembly involves oxidation of lysine residues catalyzed by the Lox enzyme, which converts an εNH 2 -group of a lysine residue to an aldehyde group, generating an allysine residue (Fig. 6) . Allysine residues undergo spontaneous condensation with other lysine resides, generating Pyd and Dpd crosslinks in mature collagen fibers (Fig. 6) . These intermolecular crosslinks are essential for mechanical properties and stability of collagen fibrils. Deficiencies in collagen crosslinking lead to connective tissue abnormalities (14, 15, 37) . Our present findings strongly suggest that connective tissue abnormalities observed in HHcy are caused by N-homocysteinylation of lysine residue K160 located in the non-helical N-telopeptide region of Col1A1, which reduces the pyridinoline crosslink formation.
That HHcy may interfere with the collagen crosslink formation has been proposed in 1960s (38) and subsequently substantiated by studies that demonstrated reduced collagen crosslinking in CBS-deficient patients (39) and animal models of HHcy (40, 41) . However, an underlying mechanism by which HHcy reduces collagen crosslinking remained unknown.
In the past, several attempts have been made to explain mechanistic basis of collagen crosslinking abnormalities in HHcy. For example, it has been suggested that defects in dermal collagen in CBS-deficient patients are due to the condensation of Hcy with the precursor aldehyde residues (allysine) in collagen forming tetrahydrothiazine adducts (39). However, although free Hcy and aldehydes easily form stable tetrahydrothiazines (25, 42) , such adducts have not been identified in collagen (39).
Biochemical studies of the Lox enzyme show that Hcy-thiolactone, a metabolite that accumulates in HHcy in mice and humans (34, 43) , irreversibly inhibits the Lox enzyme activity by reacting with the active site lysine tyrosylquinone cofactor (31) . However, our present findings that the Lox activity is not reduced by overproduction of Hcy-thiolactone in the Cbs -/-mouse model indicates that this reaction does not occur in this animal model.
Tissue culture studies suggest that reduced collagen crosslinking may be due to the inhibition of Lox enzymatic activity (31) and expression (44) Our present findings identify a novel pathogenic consequence of N-homocysteinylationreduced pyridinoline crosslink formation in collagen-which provides a long-sought mechanistic explanation regarding how HHcy can lead to connective tissue abnormalities (38) . These findings support the following mechanism (Fig. 7) . HHcy greatly enhances ATP-dependent metabolic conversion of Hcy to Hcy-thiolactone catalyzed by MetRS (Table I and (Reaction 1a)
(Reaction 1b)
Hcy-thiolactone modifies lysine residues in collagen, which generates N-Hcy-collagen containing a free thiol group (Reaction 2).
εNH 2 -Lys-collagen + Hcy-thiolactone  εNH-(Hcy-SH)-Lys-collagen (Reaction 2)
Because collagen type I, the most abundant of all collagens, does not contain cysteine residues in its primary structure, the -SH of N-Hcy residue is the sole thiol that is present in mature collagen trimers (Fig. 7) . This thiol engages in a disulfide bond formation with a thiol of free Hcy affording S-Hcy Concomitant with elevated levels of N-Hcy in collagen, we observed reductions in collagen Pyd/Dpd crosslinks levels in the bone, tail, heart (Fig. 3) , and plasma (Fig. 4, Table IV ) of Cbs -/-mice.
These reductions in collagen crosslinking in Cbs -/-mice are consistent with the fact that crosslinking and N-homocysteinylation (Table III) both target the same lysine residue K160 located in the nonhelical N-telopeptide region of Col1A1 (13, 36) .
Our present in vivo findings that N-homocysteinylation impairs collagen crosslinking are consistent with an early in vitro study that examined relationships between chemical modifications of collagen lysine residues and crosslinking (55) . That study found that modification of collagen lysine ε-amino groups with ethyl acetimidate prevented crosslinking, which was assessed indirectly by measuring collagen physicochemical properties such as molecular size and solubility (55).
Our findings that plasma levels of collagen degradation products, soluble Dpd crosslink and crosslinked C-terminal telopeptide of collagen type I (CTX I), were reduced in plasma of Cbs -/-mice suggest two scenarios: (i) reduced collagen crosslinking or (ii) suppressed bone collagen turnover in Cbs -/-mice relative to wild type animals. We favor the first scenario because mouse Cbs deficiency does not affect bone collagen level (Fig. 3) , and tends to reduce crosslinking of bone collagen (Fig. 4) .
The second scenario is unlikely because plasma levels of PICP, a marker of collagen synthesis, were not affected by Cbs genotype (Table IV) . Thus, reduced levels of plasma total Dpd and CTX I reflect reduced crosslinking of bone collagen, most likely due to elevated N-homocysteinylation of collagen in Cbs -/-mice (Fig. 1) . Plasma CTX I, but not markers of collagen I and III synthesis (PICP and Nterminal propeptide of procollagen III), are reduced also in CBS-deficient patients (56) , which suggests that HHcy similarly effects collagen metabolism in mice and humans.
Lox is responsible for the first step in crosslink formation by oxidizing collagen lysine residues to allysine. Because decreased level of Lox activity impairs crosslinking (15) Fig. 6 ).
Our findings that collagen levels were elevated in the tail and heart of Cbs In conclusion, our data support a mechanism that explains at least in part the connective tissue abnormalities observed in HHcy mice and humans. In this mechanism HHcy increases the conversion of Hcy to, and accumulation of, Hcy-thiolactone, which then causes N-homocysteinylation of collagen lysine residues, which in turn impairs the formation of pyridinoline crosslinks important for collagen fibril structure/function. Our data point to a critical role of lysine residue K160 located in N-telopeptide of Col1A1 in this mechanism. Tissue-specific alterations in collagen accumulation can also contribute to connective tissue abnormalities in HHcy. a Data are shown as means±SD. P values were calculated using two-tailed t-test. Adjusted means for plasma CTXI were calculated using the log-transformed data. These were exponentiated to obtain adjusted values on the original scale. 
FOOTNOTES
